Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes - PubMed (original) (raw)

Randomized Controlled Trial

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

Ananda Basu et al. Diabetes Care. 2006 Mar.

Abstract

Objective: Pioglitazone, a peroxisome proliferator-activated receptor agonist and glipizide, an insulin secretagogue, are commonly used to treat type 2 diabetes. Our study was designed to examine the effects of pioglitazone versus glipizide on body water, body composition, and hemodynamic parameters in the presence of comparable glycemic control between groups.

Research design and methods: We studied 19 diabetic subjects randomly assigned to either 45 mg pioglitazone (n = 8) or 10 mg (median dose) glipizide (n = 11) for 12 weeks. Body water content was measured with deuterated water, body composition by dual-energy X-ray absorptiometry and computed tomography, and cardiac output and systemic vascular resistance by acetylene rebreathing technique both before and after therapy.

Results: Pioglitazone increased (P < 0.001 from baseline) total body water (+2.4 +/- 0.5 l) accounting for 75% of the total weight gain (+3.1 +/- 2.0 kg) but did not alter vascular endothelial growth factor concentrations. Total abdominal (-32.2 +/- 19 cm(2)) and visceral fat area (-16.1 +/- 8 cm(2)) tended to decrease with pioglitazone but increased (P < 0.02 for differences between groups) with glipizide (+38.4 +/- 17 cm(2) abdominal; +19.1 +/- 9 cm(2) visceral). Pioglitazone tended to reduce (P = 0.05) diastolic (-8.4 +/- 4 mmHg) and mean (-9.5 +/- 5 mmHg; P = 0.08) blood pressure and reduced (P < 0.001) systemic vascular resistance (2,785 +/- 336 vs. 2,227 +/- 136 dynes/s per m(2)), while there were no differences in these parameters with glipizide. Neither therapy altered circulating catecholamine concentrations.

Conclusions: When pioglitazone and glipizide are given in doses sufficient to achieve equivalent glycemic control in people with type 2 diabetes, pioglitazone increases total body water, thereby accounting for the majority of weight gain, tended to decrease visceral and abdominal fat content and blood pressure, and reduces systemic vascular resistance.

PubMed Disclaimer

Cited by

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Karalliedde J, Buckingham RE. Karalliedde J, et al. Drug Saf. 2007;30(9):741-53. doi: 10.2165/00002018-200730090-00002. Drug Saf. 2007. PMID: 17722967 Review.
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
Wu L, Gunton JE. Wu L, et al. Int J Mol Sci. 2019 Nov 21;20(23):5853. doi: 10.3390/ijms20235853. Int J Mol Sci. 2019. PMID: 31766545 Free PMC article. Review.
Body composition changes in diabetes and aging.
Al-Sofiani ME, Ganji SS, Kalyani RR. Al-Sofiani ME, et al. J Diabetes Complications. 2019 Jun;33(6):451-459. doi: 10.1016/j.jdiacomp.2019.03.007. Epub 2019 Apr 3. J Diabetes Complications. 2019. PMID: 31003924 Free PMC article. Review.
Effects of lobeglitazone on insulin resistance and hepatic steatosis in high-fat diet-fed mice.
Choi BH, Jin Z, Yi CO, Oh J, Jeong EA, Lee JY, Park KA, Kim KE, Lee JE, Kim HJ, Hahm JR, Roh GS. Choi BH, et al. PLoS One. 2018 Jul 6;13(7):e0200336. doi: 10.1371/journal.pone.0200336. eCollection 2018. PLoS One. 2018. PMID: 29979770 Free PMC article.

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes - PubMed (original) (raw)